Sparks commentary - Cantargia

Healthcare

Sparks - Cantargia

More on this equity
Cantargia (OMX: CANTA) breast cancer study fully recruited
Published by Arron Aatkar, PhD

Cantargia has announced that it has completed recruiting patients (n=102) for the randomised Phase II TRIFOUR trial, which is evaluating nadunolimab in combination with platinum-based chemotherapy, compared to chemotherapy alone, in triple negative breast cancer. The initial efficacy results are anticipated from mid-2025, potentially representing a near-term catalyst for the company.

The prior interim update from the Phase Ib dose-finding portion of the programme (n=15) were encouraging, showing an overall response rate of 60%, median progression-free survival of 6.6 months and overall survival of 12.8 months.

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free